Clinical Trial Update: A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a gadolinium-based contrast agent for adults undergoing MRI to evaluate abnormal vascular lesions outside the CNS; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abnormal Vascular Lesions of Body Regions Excluding the Central Nervous System

Snippet

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd | Conditions: For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) | Phase 3 | Status: COMPLETED